GlaxoSmithKline and Pfizer are combining their consumer healthcare businesses in a multibillion-dollar merger.
The two pharmaceutical giants — which own household names like Advil and Tums — said Wednesday that the new company would have combined sales of $12.7 billion a year.
The merger will bring together Pfizer's big sellers like Centrum and Caltrate with GSK's top brands, including Excedrin and Nicorette.
After the tie-up, GSK said it plans to split in two by spinning off the new consumer healthcare business and listing it in London within three years. GSK's remaining operations will be focused on making prescription medicines and vaccines.
"Our goal is to create two exceptional, UK-based global companies," GSK CEO Emma Walmsley said in a statement.
GSK shares jumped more than 7% in London following the announcement.
- Advil meet Excedrin: Pfizer and GSK are merging their consumer healthcare businesses
- Pfizer issues voluntary recall of children's Advil
- Pfizer to raise prices on Lyrica, Viagra, 39 other medications
- Pfizer to buy Array BioPharma for $11 billion
- Former HIV clinic now offering primary healthcare
- Sparkman Middle School hosts Merge Day for elementary students
- New program merges Huntsville historically black colleges and universities together
- Tesla tanks on Consumer Reports reliability study
- Which Advertising Medium Do Consumers Trust the Most?
- WATCH: Lava "blob" consumes car in Hawaiian community